Astel­las writes down an­oth­er piece of its Au­dentes gene ther­a­py ac­qui­si­tion

Astel­las will take a $450 mil­lion (70 bil­lion Japan­ese yen) hit in its lat­est quar­ter as it writes down the val­ue of a pre­clin­i­cal gene ther­a­py pro­gram and an ane­mia treat­ment al­ready on the mar­ket.

More than half of the im­pair­ment loss — al­most $260 mil­lion (40 bil­lion Japan­ese yen) — is tied to AT808, a gene re­place­ment ther­a­py for Friedre­ich’s atax­ia. An­oth­er $100 mil­lion con­cerns the Fi­bro­Gen-part­nered re­nal ane­mia drug Evren­zo, whose sales have dis­ap­point­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER